German diabetes DMP (disease management programme) severely flawed, say experts
This article was originally published in Clinica
The German government's disease management programme (DMP) for the treatment of diabetes mellitus type II offers nothing new and in certain respects represents a decline in current procedure standards, says the German diabetes society (DDG). The claims have been made in response to the health ministry's publication of the prerequisites for the introduction of a DMP for diabetes mellitus type II.
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.